Pulmonary Function Archives

FDA Approves First Biologic for SSc-ILD

Adults, Approvals, Autoimmune Diseases, Biologics, Blockbusters, Clinical Trials, FDA, Genentech, Immune System, New Indications, Pulmonary Function, R&D, Rheumatoid Arthritis, Scleroderma, Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD), Therapeutics, Ventilators

The U.S. Food and Drug Administration approved Genentech’s Actemra (tocilizumab) for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

March 5, 2021/by Andrew Humphreys

FDA Approves Boehringer Ingelheim’s Ofev

Approvals, Center for Drug Evaluation and Research (CDER), FDA, FDA/Regulatory, First-In-Class, Idiopathic pulmonary fibrosis (IPF), Priority Review, Pulmonary Function, Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

The U.S. Food and Drug Administration gave the thumbs-up to Boehringer Ingelheim’s Ofev (nintedanib) for systemic sclerosis-associated interstitial lung disease.

September 9, 2019/by BioSpace